Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Macular Degeneration Choroidal Neovascularization Clear all
Completed Phase 2Phase 3 Interventional

Phase II/III Study of Anti-VEGF in Neovascular AMD

NCT00021736
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
EYE001 anti-VEGF aptamer
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:12 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

NCT01021956
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
STAKEL
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • West Columbia, South Carolina • Harlingen, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

NCT03823300
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

NCT02397954
View directory record Official record
Conditions
Idiopathic Polypoidal Choroidal Vasculopathy
Interventions
Avacincaptad Pegol
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Jul 23, 2026, 10:12 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

NCT07496567
View directory record Official record
Conditions
Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
Interventions
Tiespectus, Aflibercept
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
50 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
48
States / cities
Gilbert, Arizona • Encino, California • Mountain View, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

NCT03823287
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 4 Interventional Results available

Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration

NCT00473642
View directory record Official record
Conditions
Age-Related Maculopathy, Choroidal Neovascularization
Interventions
Ranibizumab, Verteporfin
Drug
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 1Phase 2 Interventional

A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

NCT00363714
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
AGN211745
Drug
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2008 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD

NCT03024424
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization, Genetic Counseling
Interventions
Early disclosure, Late disclosure
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)

NCT01175395
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
IBI-20089/Lucentis
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 1 Interventional

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

NCT03249740
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
GB-102, Aflibercept
Drug
Lead sponsor
Graybug Vision
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)

NCT00492284
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
verteporfin, ranibizumab, dexamethasone
Drug
Lead sponsor
QLT Inc.
Industry
Eligibility
50 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
21
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 1Phase 2 Interventional

Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

NCT01570790
View directory record Official record
Conditions
Combretastatin A4 Phosphate, Age-related Macular Degeneration, AMD, CNV, Choroidal Neovascularization
Interventions
Combretastatin A-4 Phosphate
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration

NCT00259753
View directory record Official record
Conditions
Macular Degeneration
Interventions
Bevasiranib
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Artesia, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 1 Interventional

Fluocinolone Implant to Treat Macular Degeneration

NCT00008515
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Fluocinolone
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 3 Interventional

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

NCT00090623
View directory record Official record
Conditions
Macular Degeneration
Interventions
rhuFab V2 (ranibizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jul 23, 2026, 10:12 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

NCT05984927
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
NG101 AAV gene therapy
Genetic
Lead sponsor
Elisigen, Inc.
Industry
Eligibility
50 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
2
States / cities
Cincinnati, Ohio • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

NCT01023295
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
fosbretabulin, Saline
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2011 · Synced Jul 23, 2026, 10:12 AM EDT
Completed No phase listed Observational

Retinal Therapy Guided by 3D OCT Image Analysis

NCT02308215
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Not listed
Lead sponsor
Michael Abramoff
Other
Eligibility
45 Years to 120 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Ranibizumab and Reduced Fluence PDT for AMD

NCT00527475
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, verteporfin
Drug
Lead sponsor
Texas Retina Associates
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Santa Barbara, California • Ann Arbor, Michigan • Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jul 23, 2026, 10:12 AM EDT
Not listed Phase 1 Interventional

Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration

NCT00767949
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
iSONEP
Biological
Lead sponsor
Lpath, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2012 · Synced Jul 23, 2026, 10:12 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System

NCT00100087
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Ocular Brachytherapy
Device
Lead sponsor
Theragenics Corporation
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:12 AM EDT
Not listed Phase 1Phase 2 Interventional

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

NCT02599064
View directory record Official record
Conditions
Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization, Subretinal Scarring, Subretinal Fibrosis
Interventions
RXI-109
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Jul 23, 2026, 10:12 AM EDT
Completed Phase 4 Interventional

Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)

NCT01863199
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Lucentis (Treat and extend), Lucentis every 4 weeks, Lucentis every 12 weeks
Drug
Lead sponsor
Retinal Consultants of Arizona
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Jul 23, 2026, 10:12 AM EDT